Prescribed or provided at three of every five visits, drugs are the most commonly used weapons in the therapeutic arsenal of the office-based doctor. This finding, along with other highlights of drug utilization that appear in this report, emerged from the National Ambulatory Medical Care Survey (NAMCS), a year-long sample survey of the Nation's officebased physicians, conducted in 1985 by the National Center The data-collection instrument used in the survey. the Patient Record, appears as figure 1. Item 14 of the Patient Record required responding physicians to enter the names of up to five of the specific drugs that they prescribed or provided in the course of the office visit. (Drugs ordered through telephone contact were not included. ) This resulted in an estimated 693.4 million drug mentions, an average of 1.1 drug mentions for each of the 636.4 million oftlce visits made during the survey year. Physicians were asked to report nonprescription as well as prescription drugs, to distinguish between new and continued medications, and to indicate whether the drug was intended for the principal diagnosis associated with the visit or used for some other reason.
The overall importance of drug therapy is made graphically evident in figure 2. An estimated 61 percent of all oftlce visits were "drug visits"; that is, visits during which one or more drugs were prescribed or provided. Furthermore, in a sharply prominent 72 percent of these 389.5 million drug visits, drug therapy was the only form of treatment used. [ and Health Statistics. No. 128. DHHS Pub. No. (PHS) 87-I250. Public Health Service, Hyattsville, Md., Jan. 23, 1987. .4
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The great majority (77 percent) of the drug mentions were applied to the principal diagnoses.
A respectable tendency toward generic prescribing is suggested by the finding that 19 percent of drug entries use the generic name of the drug.
About one of every five dmg mentions was a fixed-ratio combination drug. Combinations have the advantage of offering more convenience to the patient but the off-setting disadvantages of a usually higher cost and of less flexibility in dosage adjustment due to their fixed-ratio composition.
A small but critical proportion (8 percent) of drug mentions were controlled drugs. Controlled medications have signif icant potential for addiction or habituation. Because of this potential, they are under the regulatory control of the Drug Enforcement Agency (DEA), art agency of the Department of Justice. In table 1, drugs are characterized by their DEA control level ("schedule"). Each successive schedule, from II through V, reflects a decreasing potential for addiction. With a membership consisting chiefly of the minor tranquilizers (diazepam and alprazolam, for example), the Schedule IV drugs command the highest frequency of mention. Tables 2 and 3 offer ranked listings of the 50 drugs most frequently prescribed or provided by the office-based practitioner. Table 2 uses entry names, that is, the trade or generic names entered by the physician on the prescription or other medical record. Table 3 , because its list is based on the generic ingredients of the drugs (whether in single-entity or combination form), provides a more complete perspective of drug utilization in the doctor's office. The 50 drugs listed are present in almost two-thirds of the 693.4 million drug mentions.
Another useful overview of 1985 drug utilization appears in The remaining numbered tables reveal the relationship between drug utilization and certain key variables in off]ce based care: the principal diagnosis (table 5), age and sex  of patient (table 6), race and ethnicity of patient (table 7) , and characteristics of the attending physician (table 8) .
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Of the numerous ways to measure drug utilization, tables 5-8 make use of form .
One-the literal number of drug mentions for a given variable, the most exact measurement of overall volume of utilization. . Two-the proportion of visits during which one or more drugs were prescribed or provided, a useful insight into the.jrequerzcy of drug use. .
Three-the proportion of visits during which two or more drugs were prescribed or provided, an indicator of the intensi~ of use. . Four-the Drug Utilization Index, an artifactual indicator of frequency plus intensity formed by combining propor tions two and three above.
Diagnosis
Proper evaluation of the patterns of drug utilization requires that the data user look first to the morbidity that the drugs were intended to prevent, diagnose, or treat. The most direct and frequent linkage occurs here. In rational prescribing, a drug is seldom if ever utilized for the sole reason that the patient is over 65, or black, or female; or that the physician is an internist or a general practitioner. When variations in the substance and rhythm of utilization occur, they usually reflect differing patterns of morbidity.
It is fundamental, then, to first examine office-based drug utilization in terms of its diagnostic correlates. Table 5 makes this exploration, using the drug data specific to the first-listed (principal) diagnosis associated with each office visit (fig ure 1, item 11a). It is readily evident that two major diagnostic groups-respiratory disease and circulatory disease~ominate the world of office-based drug utilization, a dominance that is evident in all the various measures of utilization.
.
The respiratory and circulatory disease diagnostic groups account for the highest respective proportions of total drug mentions (20 percent for respiratory disease and 16 percent for circulato~). . They lead the other major diagnostic groups in the propor tion of office visits during which one or more drugs were prescribed or provided (83 percent for respiratory disease and 75 percent for circulatory).
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They lead the other groups in the proportion of visits at which multiple drug mentions appear.
For each, therefore, the Drug Utilization Index, the com bined indicator of frequency and intensity, well exceeds the Index for any other diagnostic group.
Patient
Along the continuum of patient age there were two peak � in dmg utilization; this was tme regardless of the method of measurement employed. There was a minor peak in the youngest age group, due largely to the more than average use of antibiotics and immunizations, and a major peak in . the oldest age group, resulting largely fi-om the presence-at based on simple enumeration of drug mentions should be times concomitant+f the chronic diseases that afflict the treated with caution. It is tme that drug mentions for female ging. It is noteworthy that these oldest patients, though they patients substantially outnumber mentions for males-in a o made up only 12 percent of the population, accounted for ratio of roughly 6 to 4. But this ratio also holds 'for office 20 percent of ot%ce visits and nearly 30 percent of all drug visits in general, where it is influenced to a pronounced extent mentions (table 6) .
by the presence of conditions and needs that are unique to The relationship between the sex of the patient and drug the female and by the demographic fact that, in 1985, females utilization requires careful evaluation: A gender comparison outlived males by an average of 7 years, producing more 1A composite indicator of the frequency and intensity of drug utilization, formsd by adding the percent of visits with 1 drug mention or more to the percent of visits with multiple drug mentions and rounding to the nearest whole integer.
. 8 advalux?dm 1A composite indicator of the frequency and intensity of drug utilization, formed by adding the percent of visits with 1 drug mention or mora to the percent of visits with multiple drug mentions and rounding to the nearest whole integer.
female visits at the oldest end of the age spectrum. On the their white counterpwts do. General practitioners, as a referother hand, from the perspective of the Drug Utilization Inence to table 8 will reveal, utilize drug therapy with a frequency dexes, the gender difference in average frequency and intensity and intensity that exceeds that of most of the more specialized of drug utilization is not very great. To be fair, contrasts physicians. between male and female drug utilization should be based on average tendencies, should be diagnosis-specific within
Physician
common age groups, and should control for agents that are unique to either sex. This subject will be explored further
In comuarinz the Drug Utilization Indexes, it is cle o ..-in future reports from the NAMCS drug database.
that Doctors of Osteopathy-as a group exceeded Doctors of Contributing to the significantly higher Drug Utilization Medicine in the average extent to which they utilized drug Index for office visits by black patients (table 7) is the fact therapy (table 8) . This may be chiefly because the clear majorthat black patients favor the general practitioner more than ity of their members engage in general practice, and general * actitioners-as the specialty findings in table 8 make evi t-lead most of the other specialists in the tempo and ume of their drug utilization. Every method of measuring drug utilization offers strong evidence of the prominent roles played by three primary care providers: general practitioners, family physicians, and inter nists (table 8) . As a group they account for a majority (54 percent) of all drug mentions, and their indicators of utilization are higher than those of any other specialists except physicians whose primary focus is limited to cardiovascular disease.
Noteworthy contrasts between 1985 and 1981 drug findings
Prior to the 1985 survey, NAMCS was last fielded in 1981. A comparison of the dmg findings between the two survey years reveals that .
Although the absolute number of drug mentions increased over the period in rough parallel with the increased number of office visits, the average utilization patterns, as measured by the Drug Utilization Index, did not change significantly (89 for 1985; 90 for 1981) .
In 1985 Movement of specific agents within the drug classes is apparent from the findings in tables 9 and 10. They gener ally support the changes noted above for their parent classes; note, for example, the marked increase in mention number found for the nonsteroidal anti-inflammatory agents "ibuprofen" and "naproxen. 
Technical notes Source of data and sample design
The information presented in this report is based on data collected by means of the 1985 National Ambulatory Medical Care Survey (NAMCS) during the period from March 1985 through February 1986. The target universe of NAMCS com prises office visits made within the coterminous United States to non-Federal physicians who are principally engaged in office ,practice, but not in the specialties of anesthesiology, pathology, or radiology. Telephone contacts and nonoffice visits are excluded.
NAMCS uses a multistage probability sample design that involves samples of primary sampling units (PSU'S), physician practices within PSU'S, and patient visits within physician practices. For 1985, a sample of 5,032 non-Federal, officebased physicians was selected from master files maintained by the American Medical Association and the American Os teopathic Association. The physician response rate was 70.2 percent. Sampled physicians were asked to complete Patient Records (figure 1) for a systematic random sample of their office visits over a randomly assigned 1-week reporting period. Responding physicians completed 71,594 Patient Records. Characteristics of the physician's practice, such as prim specialty and type of practice, were obtained during an in tion interview. NORC (formerly known as the National O a ion Research Center), under contract to the National Center for Health Statistics, was responsible for the survey's data collection and processing operations.
Sampling errors
The standard error is a measure of the sampling variability that occurs by chance when only a sample, rather than an entire universe, is surveyed. The relative standard error of an estimate is obtained by dividing the standard error by the estimate itselfi the result is then expressed as a percent of the estimate. These measurements are applied to office visits in tables I and II; in tables III and IV they are applied to drug mentions.
Rounding of numbers
Estimates have been rounded to the nearest thousand. For this reason detailed figures within tables do not always add to totals. Rates and percents were calculated from original, unrounded figures and therefore will not necessarily agree precisely with rates or percents calculated from rounded data.
Definitions of terms used in this report
A visit is a direct personal exchange between an ambu@ tory patient seeking health care and a physician or staff member working under the physician's supervision who provides that care.
A drug mention is the physician's entry of a pharmaceuti cal agent prescribed or provided-by any route of administra tion-for prevention, diagnosis, or treatment. Generic names as well as brand-name drugs are included, as are nonprescrip tion as well as prescription drugs. Along with all new drugs, the physician also records continued medications, if the patient was specifically instructed during the visit to continue the medicaticm. 
